A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

被引:1
作者
Wang, Yun [1 ]
Liu, Xiaohua [2 ,3 ]
Peng, Daihui [2 ]
Wu, Yan [2 ]
Su, Yun'ai [4 ]
Xu, Jia [5 ]
Ma, Xiancang [6 ]
Li, Yi [7 ]
Shi, Jianfei [8 ]
Cheng, Xiaojing [9 ]
Rong, Han [10 ]
Fang, Yiru [1 ,3 ,11 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Div Mood Disorders, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Dept Psychiat, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai Key Lab Psychot Disorders, Shanghai, Peoples R China
[4] Peking Univ, Hosp 6, Dept Psychiat, Beijing, Peoples R China
[5] Harbin First Specif Hosp, Dept Psychiat, Harbin, Peoples R China
[6] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Psychiat, Xian, Peoples R China
[7] Wuhan Mental Hlth Ctr, Dept Psychiat, Wuhan, Peoples R China
[8] Hangzhou Seventh Peoples Hosp, Dept Psychiat, Hangzhou, Peoples R China
[9] Shandong Mental Hlth Ctr, Dept Psychiat, Shandong, Peoples R China
[10] Shenzhen Kangning Hosp, Dept Psychiat, Shenzhen, Peoples R China
[11] CAS Ctr Excellence Brain Sci & Intelligence Tec, Shanghai, Peoples R China
关键词
major depressive disorder; melancholic depression; fluoxetine; bupropion; cognitive behavioral therapy; brain stimulation; COGNITIVE-BEHAVIORAL THERAPY; QUICK INVENTORY; QIDS-C; DISORDER; SYMPTOMATOLOGY; STIMULATION; MOCLOBEMIDE; FLUOXETINE; EFFICACY; ADULTS;
D O I
10.2147/NDT.S303938
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Fluoxetine, bupropion, cognitive behavioral therapy (CBT), and physical therapies (modified electroconvulsive treatment or repetitive transcranial magnetic stimulation) can be used to manage melancholic depression. Objective: To compare the efficacy and safety of various treatments in patients with melancholic depression. Methods: This was a preliminary multicenter randomized controlled trial that included patients with depression in their first or recurrent acute episode between September 2016 and June 2019, and randomized to fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation. The primary endpoint was the decrease in the 17 item Hamilton Depression Rating Scale (17-HDRS). The secondary endpoint included the scores from the Quick Inventory of Depressive Symptomatology (QIDS-SR), QOL-6, and safety. Adverse events (AEs) were monitored. The follow-ups were performed at the end of the 0th, 2nd, 4th, 6th, 8th, and 12th weeks of treatment. Results: Finally, 113 patients were included in the analyses: fluoxetine (n=37), fluoxetine +CBT (n=27), fluoxetine+bupropion (n=34), and fluoxetine+bupropion+brain stimulation (n=15). The 17-HDRS and QIDS-SR scores decreased in all four groups (all P<0.05). There were no differences in the 17-HDRS scores among the four groups at the end of treatment (P=0.779), except for fluoxetine alone showing a better response regarding selfconsciousness than fluoxetine+bupropion. The QOL-6 scores increased in all four groups. The occurrence of AEs among the four groups showed no significant difference (P=0.053). Conclusion: This preliminary trial suggests that all four interventions (fluoxetine, fluoxetine +CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation) achieved similar response and remission rates in patients with melancholic depression, but that fluoxetine had a better effect on self-consciousness than fluoxetine+bupropion. The safety profile was manageable.
引用
收藏
页码:2441 / 2449
页数:9
相关论文
共 29 条
  • [1] [Anonymous], 2000, Am J Psychiatry, V157, P1
  • [2] [Anonymous], 2013, DIAGNOSTIC STAT MANU
  • [3] Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: A comprehensive review
    Bersani, Francesco Saverio
    Minichino, A.
    Enticott, P. G.
    Mazzarini, L.
    Khan, N.
    Antonacci, G.
    Raccah, R. N.
    Salviati, M.
    Delle Chiaie, R.
    Bersani, G.
    Fitzgerald, P. B.
    Biondi, M.
    [J]. EUROPEAN PSYCHIATRY, 2013, 28 (01) : 30 - 39
  • [4] Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study
    Blier, Pierre
    Ward, Herbert E.
    Tremblay, Philippe
    Laberge, Louise
    Hebert, Chantal
    Bergeron, Richard
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (03) : 281 - 288
  • [5] Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data
    Bobo, William V.
    Anglero, Gabriela C.
    Jenkins, Gregory
    Hall-Flavin, Daniel K.
    Weinshilboum, Richard
    Biernacka, Joanna M.
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2016, 31 (03) : 185 - 192
  • [6] Obsessive-compulsive disorder subtypes: an attempted replication and extension of a symptom-based taxonomy
    Calamari, JE
    Wiegartz, PS
    Riemann, BC
    Cohen, RJ
    Greer, A
    Jacobi, DM
    Jahn, SC
    Carmin, C
    [J]. BEHAVIOUR RESEARCH AND THERAPY, 2004, 42 (06) : 647 - 670
  • [7] 'Third wave' cognitive and behavioural therapies versus treatment as usual for depression
    Churchill, Rachel
    Moore, Theresa H. M.
    Furukawa, Toshi A.
    Caldwell, Deborah M.
    Davies, Philippa
    Jones, Hannah
    Shinohara, Kiyomi
    Imai, Hissei
    Lewis, Glyn
    Hunot, Vivien
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10):
  • [8] Davidson Jonathan R T, 2010, J Clin Psychiatry, V71 Suppl E1, pe04, DOI 10.4088/JCP.9058se1c.04gry
  • [9] Cognitive Behavioral Therapy for Mood Disorders: Efficacy, Moderators and Mediators
    Driessen, Ellen
    Hollon, Steven D.
    [J]. PSYCHIATRIC CLINICS OF NORTH AMERICA, 2010, 33 (03) : 537 - +
  • [10] The biological face of melancholia: Are there any reliable biomarkers for this depression subtype?
    Esposito, Cecilia Maria
    Buoli, Massimiliano
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2020, 266 : 802 - 809